Psilocybin, a rapid-acting antidepressant, reduces levels of the neuropeptide galanin and noradrenaline in cerebrospinal fluid, suggesting that normalization of these co-transmitters is a key pharmacodynamic effect. This finding comes from a secondary analysis of a randomized, placebo-controlled trial with multimodal biomarker measurements. The results indicate a selective effect of psilocybin on these specific neurotransmitters, offering insight into its mechanism of action in major depressive disorder.
Nine nurses completed a 15-week online and on-site training program to serve as facilitators in a trial of psilocybin treatment for depression in cancer patients. Subjective evaluations indicated the training supported knowledge and skill acquisition, but most nurses reported needing additional practical in-person training to feel adequately prepared. An objective assessment of verbal relational skills using role-plays showed a significant increase in only one of twelve measures, with medium to large effect sizes for six measures from pre- to post-training. The training model showed modest potential to improve outcomes, though effects were limited to role-play. The specific skills and qualifications needed for providing psychotherapeutic support in psilocybin treatment remain unclear.